Xintela AB

Research Xintela AB (XINT) on Bullrun: market cap SEK 155.03M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerXINT
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Market capSEK 155.03M
• Financial periodQ4 2025
• RevenueSEK 415.00K
• Net income-SEK 16.69M
• Free cash flow-SEK 18.61M
• Gross margin100.0%

Valuation Snapshot

latest market cap is SEK 155.03M.

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses.

Frequently asked questions

What is Xintela AB's market cap?

Xintela AB's market capitalization is SEK 155.03M.

What does Xintela AB do?

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy.